Anne O'Riordan Net Worth

The estimated Net Worth of Anne O Riordan is at least $2.95 Million dollars as of 11 August 2023. Ms. Riordan owns over 1,241 units of Jazz Pharmaceuticals plc stock worth over $1,319,487 and over the last 6 years she sold JAZZ stock worth over $406,744. In addition, she makes $1,227,120 as Independent Director at Jazz Pharmaceuticals plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Riordan JAZZ stock SEC Form 4 insiders trading

Anne has made over 3 trades of the Jazz Pharmaceuticals plc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 1,241 units of JAZZ stock worth $171,457 on 11 August 2023.

The largest trade she's ever made was selling 1,241 units of Jazz Pharmaceuticals plc stock on 11 August 2023 worth over $171,457. On average, Anne trades about 350 units every 57 days since 2019. As of 11 August 2023 she still owns at least 12,551 units of Jazz Pharmaceuticals plc stock.

You can see the complete history of Ms. Riordan stock trades at the bottom of the page.

Anne O'Riordan biography

Anne O'Riordan serves as Independent Director of the Company. Ms. O’Riordan has served as Group Director of Digital of Jardine Matheson Limited, an Asian conglomerate headquartered in Hong Kong, where she also serves on the board of directors. From 1990 to March 2019, Ms. O’Riordan held various leadership positions in the life sciences industry group in each of the operating units of Accenture (formerly Andersen Consulting) in North America, Europe and Asia Pacific. She most recently served as Global Industry Senior Managing Director of Accenture’s Life Sciences Business from 2012 to 2019. Between 2008 and 2012, Ms. O’Riordan led Accenture’s life sciences practice in Asia Pacific, focusing on strategic client development, market entry and business transformation. Prior to that, she led Accenture’s European health and life sciences business, working with clients across Europe on significant regional transformation initiatives. She also spent nine years in North America working with pharmaceutical and medical products clients. She currently serves on the board of governors of the American Chamber of Commerce in Hong Kong, or AmCham Hong Kong, where she serves as the Treasurer and the board liaison for the Healthcare Committee. She is also a long-standing member of the Women of Influence Committee of AmCham Hong Kong as well as a member of The Women’s Foundation and the 30% Club. Ms. O’Riordan received a B.Sc in Biotechnology from Dublin City University as well as a postgraduate diploma in Financial Accounting and MIS from the National University of Galway, Ireland.

What is the salary of Anne Riordan?

As the Independent Director of Jazz Pharmaceuticals plc, the total compensation of Anne Riordan at Jazz Pharmaceuticals plc is $1,227,120. There are 6 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of $14,713,600.

How old is Anne Riordan?

Anne Riordan is 52, she's been the Independent Director of Jazz Pharmaceuticals plc since 2019. There are 20 older and 7 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.

What's Anne Riordan's mailing address?

Anne's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .

Insiders trading at Jazz Pharmaceuticals plc

Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright, and Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.

What does Jazz Pharmaceuticals plc do?

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni

Complete history of Ms. Riordan stock trades at Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc executives and stock owners

Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include:

• Bruce Cozadd,
  Chairman of the Board, Chief Executive Officer
• Daniel Swisher,
  President, Chief Operating Officer
• Robert Iannone,
  Executive Vice President, Research and Development
• Neena Patil,
  Senior Vice President, General Counsel
• Bruce C. Cozadd,
  Co-Founder, Chairman & CEO
• Daniel N. Swisher Jr.,
  Pres
• Anne O'Riordan,
  Independent Director
• Dr. Robert Iannone M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Renee D. Gala,
  Exec. VP & CFO
• Kim Sablich,
  Exec. VP & GM of North America
• Rick Winningham,
  Independent Director
• Heather McSharry,
  Independent Director
• Peter Gray,
  Independent Director
• Norbert Riedel,
  Independent Director
• Patrick Enright,
  Independent Director
• Catherine Sohn,
  Independent Director
• Elmar Schnee,
  Independent Director
• Seamus Mulligan,
  Independent Director
• Kenneth O'Keefe,
  Independent Director
• Paul Berns,
  Independent Director
• Diane Schrick,
  Senior Director, Investor Relations
• Patricia Carr,
  Vice President, Finance and Principal Accounting Officer
• Samantha Pearce,
  Senior Vice President, Europe and Rest of World
• Finbar Larkin,
  Senior Vice President - Technical Operations
• Kimberly Sablich,
  Executive Vice President, General Manager - North America
• Renee Gala,
  Chief Financial Officer, Executive Vice President
• Neena M. Patil J.D.,
  Chief Legal Officer and Sr. VP of Legal & Corp. Affairs
• Andrea N. Flynn,
  VP & Head of Investor Relations
• Dr. Finbar Larkin Ph.D.,
  Sr. VP of Technical Operations
• Patricia Carr,
  VP of Fin. & Principal Accounting Officer
• Christopher John Tovey,
  Exec. VP, COO and MD of Europe & International
• Paul Treacy,
  SVP, Technical Operations
• Suzanne Sawochka Hooper,
  EVP and General Counsel
• Karen L. Smith,
  Global Head of R&D and CMO
• Karen J Wilson,
  VP of Finance & PAO
• Russell J. Cox,
  SVP, Sales and Marketing
• Iain Mc Gill,
  Head of EUSA Int'l & SVP
• Matthew P. Young,
  SVP & CFO
• Michael Patrick Miller,
  EVP, US Commercial
• Jennifer E. Cook,
  Director
• Mark Douglas Smith,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Bryan C Cressey,
  Director
• Alan Sebulsky,
  Director
• Kathryn E Falberg,
  SVP and CFO
• Paul Egolkin Perryhuth Joha...,
  
• Michael W Michelson,
  Director
• Samuel D Colella,
  Director
• Financial Holdings Iii, Llc...,
  
• Group Holdings L.P.Kkr Grou...,
  
• Matthew K Fust,
  Senior Vice President & CFO
• Jeffrey K Tobias,
  EVP, Research & Dev and CMO
• Fintan Keegan,
  EVP, Technical Operations
• Cressey Equity Partners Inc...,
  
• Mark G. Eller,
  SVP, Research & Clinical Dev.
• James C Momtazee,
  Director
• Jp Iii Llckkr Partners Iii,...,
  
• Fund Holdings L.P.Kkr Jp Ll...,
  
• Michael A. Des Jardin,
  SVP, Product Development
• Nathaniel M Zilkha,
  Director
• Joan Colligan,
  Principal Accounting Officer
• Janne Lt Wissel,
  Senior VP of Development
• James B Tananbaum,
  Director
• Samuel R Saks,
  Chief Executive Officer
• Robert M Myers,
  President
• E Alexander Albert,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Michael W Janetschek Willia...,
  
• Carol A Gamble,
  SVP, GC and Corporate Secty
• Management Llcmignone Rober...,
  
• Henry Rroberts George Rgree...,
  
• Michael Wkkr Financial Hold...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Patel Jaimin,
  Director
• Michael Wkkr Financial Hold...,
  
• Kim Sablich,
  EVP, GM of U.S.
• Mary Elizabeth Henderson,
  SVP, Technical Operations
• Christopher J. Tovey,
  EVP, COO & Managing Director E
• Laura Hamill,
  Director
• Patrick Kennedy,
  Director
• Philip L Johnson,
  EVP & Chief Financial Officer